The strong Phase 2 data for OBX-115 significantly de-risks the combined entity's lead asset and increases the probability of merger completion. Traders should watch for the S-4 registration statement effectiveness and Galera stockholder vote timeline. The ASCO presentation on June 1, 2026, could drive further upside if additional detail emerges.
Price Chart
Executive Summary
Galera Therapeutics filed a Rule 425 communication reposting Obsidian Therapeutics' LinkedIn announcement of positive Phase 2 data for OBX-115 in advanced melanoma, showing a 67% objective response rate at the recommended Phase 2 dose. This data strengthens the strategic rationale for the pending merger between Galera and Obsidian, which is supported by a $350 million PIPE and will result in a combined company trading on Nasdaq under ticker OBX.
Key Financial Metrics
Key Facts
- OBX-115 achieved 67% ORR (10/15) at RP2D in advanced melanoma, including 2 complete responses
- Data presented at 2026 ASCO Annual Meeting in oral presentation
- No dose-limiting toxicities, no ICANS, no ICU transfers, and no treatment-related mortality observed
- Merger agreement dated April 14, 2026: Galera merges into Gazelle Parent alongside Obsidian
- Combined company will list on Nasdaq as Obsidian Therapeutics (ticker OBX)
- Concurrent $350 million PIPE financing supports the combined entity
Financial Impact
No financial figures disclosed in this filing; prior filings indicate a $350 million PIPE financing supporting the merger
Risk Factors
- Merger requires Galera stockholder approval and regulatory clearance
- OBX-115 is still investigational; Phase 3 data and FDA approval are years away
- Galera currently trades on OTC; Nasdaq listing is contingent on merger closing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-235217 |
| Document: 0001193125-26-235217-index-headers.html | 0001193125-26-235217 |
| Document: 0001193125-26-235217-index.html | 0001193125-26-235217 |
| Document: 0001193125-26-235217.txt | 0001193125-26-235217 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | EFFECT | — | awaiting T+20 | — | — |
Aug 4, 2026 11w ago | 15-12G | — | awaiting T+20 | — | — |
Aug 3, 2026 11w ago | 8-K | — | awaiting T+20 | — | — |
Jul 13, 2026 15w ago | 8-K | $16.39 | awaiting T+20 | — | — |
Jul 7, 2026 15w ago | 8-K | $17.80 | awaiting T+20 | — | — |
May 21, 2026 22w ago | 425 | $0.1000 $0.0910 | ▼ −9.00% | ▼ −7.58% | — |
May 19, 2026 22w ago | 8-K | $0.1010 $0.0857 | ▲ +15.15% | ▲ +15.89% | — |
Apr 22, 2026 26w ago | 425 | $20.00 $20.20 | ▲ +1.00% | ▼ −3.22% | — |
Apr 22, 2026 26w ago | 425 | $20.00 $20.20 | ▲ +1.00% | ▼ −3.22% | — |
Apr 14, 2026 27w ago | Press Release | $0.0790 $0.1000 | ▼ −26.58% | ▼ −20.29% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers